Transdermal Estradiol for Menopausal Hot Flashes: What the Evidence Shows

How Does Hormone Therapy Reduce Menopausal Hot Flashes and Mood Symptoms?

During perimenopause and menopause, fluctuating and then declining estradiol levels destabilize the hypothalamic thermoneutral zone, narrowing the temperature range in which the body maintains equilibrium. Small changes in core body temperature can then trigger the characteristic flushing, sweating, and chills known as vasomotor symptoms. Estrogen replacement widens this thermoneutral zone, which is why systemic hormone therapy remains the most effective intervention for moderate to severe hot flashes and night sweats.

Estrogen also modulates serotonergic and noradrenergic pathways involved in mood regulation and sleep architecture. This helps explain why many women treated for vasomotor symptoms with hormone therapy also report improved sleep continuity, reduced irritability, and fewer depressive symptoms — particularly women with new-onset mood changes during the menopause transition. The Menopause Society (formerly NAMS) emphasizes in its 2022 position statement that for healthy symptomatic women under 60 or within 10 years of menopause onset, the benefits of hormone therapy generally outweigh the risks.

Why Do Clinicians Often Prefer the Transdermal Route?

Oral estrogens pass through the liver before reaching systemic circulation, where they can increase hepatic production of clotting factors, triglycerides, and C-reactive protein. Transdermal estradiol — delivered via patch, gel, or spray — enters the bloodstream directly through the skin, bypassing this first-pass effect. Observational studies and meta-analyses summarized by the Menopause Society and the European Menopause and Andropause Society suggest that transdermal delivery carries a lower venous thromboembolism risk and may be preferable for women with elevated cardiovascular or metabolic risk factors.

For women with an intact uterus, estrogen must be combined with a progestogen to protect against endometrial hyperplasia. Micronized progesterone, which has a more favorable metabolic and breast safety profile than older synthetic progestins, is now widely recommended. Clinicians tailor the formulation, dose, and route based on symptom severity, personal and family medical history, and patient preference — a marked shift from the one-size-fits-all approaches that preceded more nuanced reinterpretation of the Women's Health Initiative data.

Who Should Avoid Hormone Therapy for Menopausal Symptoms?

Absolute contraindications include hormone-sensitive cancers such as breast or endometrial cancer, active or recent venous thromboembolism, active liver disease, and unexplained vaginal bleeding. For women over 60 or more than 10 years past menopause, initiation of systemic hormone therapy is generally not recommended because cardiovascular and stroke risks tend to outweigh symptomatic benefits in this group — a concept often referred to as the timing hypothesis.

Non-hormonal alternatives have expanded significantly. The FDA approved fezolinetant, a neurokinin 3 receptor antagonist, for moderate to severe vasomotor symptoms in 2023, giving clinicians a targeted non-hormonal option for women who cannot or prefer not to use estrogen. Low-dose SSRIs and SNRIs, gabapentin, and cognitive behavioral therapy also have evidence supporting symptom reduction, though typically with smaller effect sizes than systemic estrogen.